Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1793689 | 0.80 | HRH3 (0.61) | LTA4HHRH3KCNH2MAOBPSMB1 | |
| SCHEMBL3840409 | 0.79 | MAOB (0.49) | LTA4HHRH3KCNH2MAOBESR1 | |
| SCHEMBL1795485 | 0.78 | HRH3 (0.59) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL2180695 | 0.77 | EBP (0.60) | LTA4HHRH3PTGS2MAOBESR1 | |
| SCHEMBL1797228 | 0.76 | HRH3 (0.56) | LTA4HHRH3MAOBPSMB1PSMB5 | |
| SCHEMBL1799422 | 0.76 | HRH3 (0.56) | LTA4HHRH3MAOBPSMB1PSMB5 | |
| SCHEMBL1793847 | 0.74 | HRH3 (0.54) | LTA4HHRH3MAOBPSMB1PSMB5 | |
| SCHEMBL1796247 | 0.74 | HRH3 (0.62) | HRH3KCNH2 | |
| SCHEMBL15257179 | 0.73 | LTA4H (0.82) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL14970684 | 0.73 | LTA4H (0.82) | LTA4HHRH3PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709023-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20070111988-A1 | Selective estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070066595-A1 | Selective estrogen receptor modulators | ARRAY BIOPHARMA, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1709023-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1709022-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073205-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073206-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111988-A1 | Selective estrogen receptor modulators | ESR2, GPER1, ESRRA | LTA4H 1532/4885HRH3 2187/4885KCNH2 2307/4885 |
| US-20070066595-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | LTA4H 1471/4885HRH3 2616/4885KCNH2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.